Digestive System Tumors Clinical Trial
Official title:
Phase I Clinical Study on the Safety and Tolerability of a CDK4 / 6 Inhibitor and a MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors
This is a prospective, open, phase I clinical study to evaluate the safety and tolerability of a CDK4 / 6 inhibitor and a MEK inhibitor in the treatment of metastatic digestive system tumors
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05139082 -
Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05260385 -
To Evaluate KC1036 in the Patients With Advanced Digestive System Tumors
|
Phase 1/Phase 2 |